(J Virol Methods[TA])
8,680 results
  • Stability analysis of rabies virus in the environment. [Journal Article]
    J Virol Methods. 2026 Jul 16; 346:115437. [Online ahead of print]Zhang M, Zhang N, … Zhu WJV
  • Rabies, a fatal zoonosis, remains a burden in developing countries. Concerns about indirect environmental transmission and appropriate post‑exposure prophylaxis (PEP) are increasing, yet data on RABV stability under various conditions are limited. In this study, we systematically evaluated the stability of RABV (CVS‑11 strain) on six surface (glass, rubber, plastic, polypropylene surgical mask, f…
  • Broadening the use of virus-mimicking artificial positive controls in plant virus diagnostics. [Journal Article]
    J Virol Methods. 2026 Sep; 345:115434.Atanda HY, Osundahunsi B, … Tzanetakis IEJV
  • Positive controls are essential for diagnostics yet access to high quality ones remains a persistent bottleneck for assay validation and quality control. Infected tissues are scarce or even regulated, whereas synthetic DNA fragments lack matrix effects and raise contamination risks. Here, we validate the Virus-Mimicking Artificial Positive Control (ViMAPC) platform for 18 viruses, demonstrating p…
  • Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development. [Review]
    J Virol Methods. 2026 Sep; 345:115432.Ikrar T, Muchsin W, Sophian AJV
  • CONCLUSIONS: Cross-strain protective vaccines against influenza and coronaviruses are scientifically achievable, supported by converging immunological principles and advancing clinical evidence across both fields. Accelerating translation to population-level protection requires coordinated investment in epitope-focused antigen engineering, correlate-of-protection validation, adaptive regulatory frameworks, and equitable global manufacturing capacity. Crucially, the scientific and policy lessons of COVID-19-both the remarkable speed enabled by prior platform investments and the inequities exposed in global vaccine distribution-must be integrated into universal respiratory virus vaccine programmes now, before the next pandemic forces another reactive response.